---
title: "Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)"
description: "Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therap"
url: "https://www.clareohealth.com/clinical-trials/NCT04863703"
---

Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH and is associated with an improved outcome. Recently, Bulevirtide was approved for the treatment of patients coinfected with hepatitis B (HBV) and chronic hepatitis delta (HDV) infection, which helps to achieve viral supression in these patients. This study investigates the potential effects of viral supression on PH in patients with chronic HBV/HDV infection and liver cirrhosis.

## Key Facts

**ID:** NCT04863703
**Status:** ACTIVE_NOT_RECRUITING
**Type:** OBSERVATIONAL
**Enrollment:** 11
**Sponsor:** Hannover Medical School

## Conditions

- Hepatitis D
- Hepatitis B
- Portal Hypertension
- Liver Cirrhosis

## Interventions

**DRUG: Bulevirtide**
Patients with liver cirrhosis and HBV/HDV coinfection receive Bulevirtide as an antiviral therapy irrespective of the study, this study is observational.

## Eligibility

Inclusion Criteria: * Chronic HBV/HDV Coinfection * suspected or diagnosed liver cirrhosis, indication for hepatovenous pressure gradient (HVPG) measurement or liver cirrhosis and…

## Who Can Participate

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Hannover Medical School, Hanover, Lower Saxony, Germany

## Contact Information

## Important Dates

**Study start:** May 7, 2021

**Completion date:** December 31, 2026

**Last updated:** September 15, 2025

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04863703)
